PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Understand How the Study Medicine Called ARV-471 is Processed in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05930925
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
Phase 2
Active, not recruiting
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT05926960
- Locations
- 🇩🇪
Universitaetsklinikum Tuebingen, Tübingen, Baden-württemberg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
🇩🇪Universitaetsklinikum Essen, Essen, Nordrhein-westfalen, Germany
BESPONSA Injection 1 mg Special Investigation
Completed
- Conditions
- Acute Lymphocytic Leukemia
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 421
- Registration Number
- NCT05923112
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: Single dose of PF-07220060 as first Tablet FormulationDrug: Single dose of PF-07220060 as a Tablet formulation under Rabeprazole administrationDrug: Single dose of PF-07220060 as third tablet formulationDrug: Single dose of PF-07220060 as second Tablet FormulationDrug: Single dose of PF-07220060 as a Tablet Formulation
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT05923411
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1300
- Registration Number
- NCT05912933
A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT05907395
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study of Vepdegestrant (ARV-471, PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 59
- Registration Number
- NCT05909397
- Locations
- 🇸🇰
Nemocnica na okraji mesta n o, Partizanske, Slovakia
🇺🇸BRCR Medical Center Inc, Plantation, Florida, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Solid TumorsBreast CancerOvarian CancerLiposarcomaEndometrial
- Interventions
- Combination Product: Fulvestrant
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05905341
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Phase 1
Completed
- Conditions
- PharmacokineticsHealthy Volunteers
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05898672
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age
Phase 1
Completed
- Conditions
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- Interventions
- Biological: RSVpreF 120 µgBiological: RSVpreF 60 µg
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 128
- Registration Number
- NCT05900154
- Locations
- 🇺🇸
Senders Pediatrics, South Euclid, Ohio, United States
🇺🇸University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
© Copyright 2025. All Rights Reserved by MedPath